Nintedanib
- Generic Name
- Nintedanib
- Brand Names
- Ofev, Vargatef, Nintedanib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33N5O4
- CAS Number
- 656247-17-5
- Unique Ingredient Identifier
- G6HRD2P839
- Background
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only tw...
- Indication
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It is also indicated for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
...
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Respiratory Function Impaired, Chronic Progressive Fibrosing Interstitial Lung Disease, Locally advanced Non-Small Cell Lung Carcinoma (NSCLC), Locally recurrent Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
- Associated Therapies
- -
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 586
- Registration Number
- NCT04325217
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT04093024
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇷General Hospital of Thessaloniki "Ippokrateio", Thessaloniki, Greece
🇧🇷Serviços Medicos Respirar Sul Fluminense, Barra Mansa, Brazil
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
- Conditions
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13264
- Registration Number
- NCT03958071
- Locations
- 🇺🇸
Plymouth Meeting, Plymouth, Pennsylvania, United States
A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 435
- Registration Number
- NCT03820726
- Locations
- 🇯🇵
National Hospital Organization Himeji Medical Center, Hyogo, Himeji, Japan
🇫🇷HOP Civil, Strasbourg, France
🇷🇺1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., St. Petersburg, Russian Federation
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 20
- Registration Number
- NCT03805477
- Locations
- 🇸🇦
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
🇨🇭Clinic of Hematology, University Hospital Basel, Basel, Switzerland
🇨🇭Clinic of Respiratory Medicine, University Hospital Basel, Basel, Switzerland
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT03717012
- Locations
- 🇺🇸
The LaPorte County Institute for Clinical Research, Michigan City, Indiana, United States
🇺🇸Temple University Hospital, Oaks, Pennsylvania, United States
🇺🇸Metroplex Pul and Sleep Ctr, McKinney, Texas, United States
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT03710824
- Locations
- 🇬🇷
University Hospital of Heraklion, University Pulmonology Cl, Heraklion, Greece
🇬🇷Univ. Gen. Hosp. of Ioannina, Ioannina, Greece
🇬🇷Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med., Athens, Greece
A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT03675581
- Locations
- 🇪🇸
Hospital Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
🇳🇱Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Temple University
- Target Recruit Count
- 1
- Registration Number
- NCT03562416
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 44
- Registration Number
- NCT03513484
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.